Pneumococcal and influenza vaccination

European Respiratory Monograph

Volumn 63, Issue , 2014, Pages 266-284

  Pletz, Mathias W ^a   Welte, Tobias ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; EGG PROTEIN; FLAGELLIN; HEMAGGLUTININ; HYBRID PROTEIN; INFLUENZA VACCINE; MACROLIDE; MATRIX PROTEIN; MIFAMURTIDE; PLACEBO; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VAX 102 PROTEIN; VIRUS NUCLEOPROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIOLOGY; COMMUNITY ACQUIRED PNEUMONIA; DRUG POTENTIATION; HERD IMMUNITY; HUMAN; IMMUNOPATHOLOGY; INFECTION PREVENTION; INFLUENZA; META ANALYSIS (TOPIC); MUCOSAL IMMUNITY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VIROLOGY;

EID: 84905739931     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10004913     Document Type: Article

References (110)

1. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J2002; 20: Suppl. 36, 20s-27s.
2. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67: 71-79.
3. Pletz MW, von Baum H, van der Linden M, et al. The burden of pneumococcal pneumonia-experience of the German competence network CAPNETZ. Pneumologie 2012; 66: 470-475.
4. von Baum H, Schweiger B, Welte T, et al. How deadly is seasonal influenza associated pneumonia? The German Competence Network for Community-acquired pneumonia (CAPNETZ). Eur Respir J2011; 37: 1151-1157.
5. Statens Serum Institut. Pneumococcal vaccination of persons at increased risk of invasive pneumococcal disease. www. ssi. dk/English/News/EPI-NEWS/2012/No%2051b%20-%202012. aspx Date last updated: December 19, 2012.
6. Rokottajan Käsikirja. Pneumokokkikonjugaattirokotukset (PCV) [Pneumococcal conjugate vaccine (PCV)]. www. thl. fi/fi_FI/web/rokottajankasikirja-fi/pneumokokkikonjugaattirokotukset
7. IVZ. Cepljenje proti pnevmokoknim okužbam za odrasle in otroke [Vaccination against pneumococcal infection in adults and children]. www. ivz. si/cepljenje/strokovna_javnost/navodila_in_priporocila?pi518&_18_view5item&_18_newsid52230&pl5253-18. 0 Date last updated: September 18, 2013.
8. European Centre for Disease Prevention and Control. Vaccine schedule. http://vaccine-schedule. ecdc. europa. eu/Pages/Scheduler. aspx Date last accessed: September 29, 2013.
9. European Centre for Disease Prevention and Control. Legal notice. http://ecdc. europa. eu/en/pages/legalnotice. aspx
10. Statens Serum Institut. Influenzavaccination [Influenza vaccination]. www. ssi. dk/Vaccination/Influenzavaccination. aspx Date last updated: September 25, 2013.
11. IVZ. Cepljenje proti gripi v sezoni 2013/2014 [Vaccination in the season 2013/2014]. www. ivz. si/cepljenje/strokovna_javnost/navodila_in_priporocila?pi518&_18_view5item&_18_newsid51316&pl5253-18. 0 Date last updated: September 30, 2013.
12. Pletz MW, Welte T, Klugman KP. The paradox in pneumococcal serotypes: highly invasive does not mean highly lethal. Eur Respir J2010; 36: 712-713.
13. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069.
14. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniaecolonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144-154.
15. Roca A, Hill PC, Townend J, et al. Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med 2011; 8: e1001107.
16. Putnam SD, Gray GC, Biedenbach DJ, et al. Pharyngeal colonization prevalence rates forStreptococcus pyogenes andStreptococcus pneumoniaein a respiratory chemoprophylaxis intervention study using azithromycin. Clin Microbiol Infect 2000; 6: 2-8.
17. Harboe ZB, Benfield TL, Valentiner-Branth P, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010; 50: 329-337.
18. Brueggemann AB, Griffiths DT, Meats E, et al. Clonal relationships between invasive and carriageStreptococcus pneumoniaeand serotype-and clone-specific differences in invasive disease potential. J Infect Dis 2003; 187: 1424-1432.
19. Valles X, Roca A, Lozano F, et al. Serotype-specific pneumococcal disease may be influenced by mannose-binding lectin deficiency. Eur Respir J2010; 36: 856-863.
20. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9: 213-220.
21. Espinosa-Padilla SE, Murata C, Estrada-Parra S, et al. Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine among Mexican children. Arch Med Res 2012; 43: 402-405.
22. Dagan R, Givon-Lavi N, Zamir O, et al. Reduction of nasopharyngeal carriage ofStreptococcus pneumoniaeafter administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002; 185: 927-936.
23. Millar EV, O'Brien KL, Watt JP, et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 2006; 43: 8-15.
24. Herva E, Luotonen J, Timonen M, et al. The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage ofStreptococcus pneumoniae. Scand J Infect Dis 1980; 12: 97-100.
25. Russell FM, Carapetis JR, Satzke C, et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vaccine Immunol 2010; 17: 1970-1976.
26. Veenhoven RH, Bogaert D, Schilder AG, et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clin Infect Dis 2004; 39: 911-919.
27. de Roux A, Schmole-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46: 1015-1023.
28. Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205: 1408-1416.
29. Pletz MW, Maus U, Krug N, et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008; 32: 199-206.
30. Musher DM, Manoff SB, McFetridge RD, et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011; 7: 919-928.
31. Lazarus R, Clutterbuck E, Yu LM, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011; 52: 736-742.
32. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
33. Leal J, Vanderkooi OG, Church DL, et al. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta. Pediatr Infect Dis J2012; 31: e169-175.
34. Jorgensen JH, Doern GV, Maher LA, et al. Antimicrobial resistance among respiratory isolates ofHaemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniaein the United States. Antimicrob Agents Chemother 1990; 34: 2075-2080.
35. Spika JS, Facklam RR, Plikaytis BD, et al. Antimicrobial resistance ofStreptococcus pneumoniaein the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J Infect Dis 1991; 163: 1273-1278.
36. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates ofStreptococcus pneumoniaein the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45: 1721-1729.
37. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance amongStreptococcus pneumoniaeisolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008; 7: 1.
38. Klugman KP. The successful clone: the vector of dissemination of resistance inStreptococcus pneumoniae. J Antimicrob Chemother 2002; 50: Suppl. S2, 1-5.
39. Rudolf D, Michaylov N, van der Linden M, et al. International pneumococcal clones match or exceed the fitness of other strains despite the accumulation of antibiotic resistance. Antimicrob Agents Chemother 2011; 55: 4915-4917.
40. Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergentStreptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197: 1016-1027.
41. Pletz MW, Shergill AP, McGee L, et al. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniaein the United States. Antimicrob Agents Chemother 2006; 50: 1561-1563.
42. Pletz MW, McGee L, Jorgensen J, et al. Levofloxacin-resistant invasiveStreptococcus pneumoniaein the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004; 48: 3491-3497.
43. Plessis M, Smith AM, Klugman KP. Detection of penicillin resistance inStreptococcus pneumoniaeby a seminested PCR strategy. Methods Mol Med 2001; 48: 65-75.
44. Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005; 365: 855-863.
45. Imohl M, Reinert RR, Mutscher C, et al. Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniaein Germany from 1992 to 2008. BMC Microbiol 2010; 10: 299.
46. Wierzbowski AK, Karlowsky JA, Adam HJ, et al. Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniaein Canada between 1998 and 2008. J Antimicrob Chemother 2014; 69: 59-66.
47. Link-Gelles R, Taylor T, Moore MR, et al. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. Vaccine 2013; 31: 2572-2577.
48. Truck J, Lazarus R, Jonsdottir I, et al. Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: there is no need for a vaccine program in older adults at present. Clin Infect Dis 2012; 55: 1577-1579.
49. Mann B, Thornton J, Heath R, et al. Broadly protective protein-based pneumococcal vaccine comprised of pneumolysin toxoid-CbpA peptide recombinant fusion protein. J Infect Dis2013 [In press DOI: 10. 1093/infdis/jit502].
50. Schulz C, Hammerschmidt S. Exploitation of physiology and metabolomics to identify pneumococcal vaccine candidates. Expert Rev Vaccines 2013; 12: 1061-1075.
51. Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66: 378-383.
52. Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1: CD000422.
53. Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ2009; 180: 48-58.
54. Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ2010; 340: c1004.
55. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typableHaemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367: 740-748.
56. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-1348.
57. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362: 812-822.
58. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355: 2106-2111.
59. Stoehr GA, Rose MA, Eber SW, et al. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. Br J Haematol 2006; 132: 788-790.
60. Russell FM, Licciardi PV, Balloch A, et al. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine 2010; 28: 3086-3094.
61. Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J2006; 25: 920-929.
62. Rose MA, Schubert R, Strnad N, et al. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin Diagn Lab Immunol 2005; 12: 1216-1222.
63. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). Am J Transplant 2013; 13: 232-235.
64. Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA1993; 90: 4171-4175.
65. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ2013; 347: f5061.
66. World Health Organization. Influenza: vaccine use. www. who. int/influenza/vaccines/use/en/Date last updated: 2013.
67. Centers for Disease Control and Prevention. Persons at Risk for Medical Complications Due to Influenza. www. cdc. gov/flu/professionals/acip/2013-summary-recommendations. htm#at-risk Date last update: August 20, 2013.
68. Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344: 889-896.
69. Wolfe RM. Update on adult immunizations. J Am Board Fam Med 2012; 25: 496-510.
70. Rebmann T, Zelicoff A. Vaccination against influenza: role and limitations in pandemic intervention plans. Expert Rev Vaccines 2012; 11: 1009-1019.
71. Rhorer J, Ambrose CS, Dickinson S, et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009; 27: 1101-1110.
72. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361: 1260-1267.
73. Kanegae Y, Sugita S, Endo A, et al. Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season. J Virol 1990; 64: 2860-2865.
74. Lo YC, Chuang JH, Kuo HW, et al. Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011-12 season. PLoS One 2013; 8: e58222.
75. Kieninger D, Sheldon E, Lin WY, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versusinactivated trivalent influenza vaccine: a phase III, randomized trial in adults agedo18 years. BMC Infect Dis 2013; 13: 343.
76. Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccineversustrivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207: 1878-1887.
77. Reed C, Meltzer MI, Finelli L, et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30: 1993-1998.
78. Centers for Disease Control and Prevention. CDC advisory committee recommends an influenza vaccine option for persons with egg allergy. www. cdc. gov/media/releases/2013/a0620-FluBlok. html Date last updated: June 21, 2013.
79. Zimmerman RK, Lin CJ, Ross T, et al. Randomized clinical trial of high-dose influenza vaccine in nursing home residents. https://idsa. confex. com/idsa/2013/webprogram/Paper43076. html
80. Ansaldi F, Canepa P, Ceravolo A, et al. Intanza115 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine 2012; 30: 2908-2913.
81. Young F, Marra F. A systematic review of intradermal influenza vaccines. Vaccine 2011; 29: 8788-8801.
82. Baldo V, Baldovin T, Pellegrini M, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol, 2010: 517198.
83. de Roux A, Marx A, Burkhardt O, et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine 2006; 24: 1537-1542.
84. Cheuk DK, Chiang AK, Lee TL, et al. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev 2011; 3: CD006505.
85. Eckerle I, Rosenberger KD, Zwahlen M, et al. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One 2013; 8: e56974.
86. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One 2011; 6: e29249.
87. Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006; 3: CD004876.
88. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518-527.
89. Jefferson T, Rivetti A, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012; 8: CD004879.
90. Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; 7: CD001269.
91. Tessmer A, Welte T, Schmidt-Ott R, et al. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J2011; 38: 147-153.
92. Avery RK. Influenza vaccines in the setting of solid-organ transplantation: are they safe?Curr Opin Infect Dis 2012; 25: 464-468.
93. Touma Z, Gladman DD, Urowitz MB. Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. Curr Opin Rheumatol 2013; 25: 164-170.
94. Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011; 258: 1197-1206.
95. Fairhead T, Hendren E, Tinckam K, et al. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. Transpl Infect Dis 2012; 14: 575-583.
96. Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant 2011; 11: 2020-2030.
97. Hurst FP, Lee JJ, Jindal RM, et al. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol 2011; 6: 1192-1197.
98. Smith AM, Adler FR, Ribeiro RM, et al. Kinetics of coinfection with influenza A virus andStreptococcus pneumoniae. PLoS Pathog 2013; 9: e1003238.
99. Launes C, de-Sevilla MF, Selva L, et al. Viral coinfection in children less than five years old with invasive pneumococcal disease. Pediatr Infect Dis J2012; 31: 650-653.
100. Kash JC, Walters KA, Davis AS, et al. Lethal synergism of 2009 pandemic H1N1 influenza virus andStreptococcus pneumoniaecoinfection is associated with loss of murine lung repair responses. mBio 2011; 2: e00172-11.
101. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus andStreptococcus pneumoniae. J Infect Dis 2003; 187: 1000-1009.
102. Alicino C, Iudici R, Alberti M, et al. The dangerous synergism between influenza andStreptococcus pneumoniae and innovative perspectives of vaccine prevention. J Prev Med Hygiene 2011; 52: 102-106.
103. Hedlund J, Christenson B, Lundbergh P, et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine 2003; 21: 3906-3911.
104. Christenson B, Lundbergh P, Hedlund J, et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001; 357: 1008-1011.
105. Schwarz TF, Flamaing J, Rumke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults agedo65 years. Vaccine 2011; 29: 5195-5202.
106. Ayala-Montiel O, Mascarenas de los Santos C, Garcia-Hernandez D, et al. Reactogenicidad de la administración simultanea de las vacunas contra influenza y neumococo en adultos mayores de 55 años de edad [Reactogenicity of the simultaneous administration of influenza and pneumococcal vaccines in adults over 55 years of age]. Rev Invest Clin 2004; 56: 27-31.
107. Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Op Immunol 2011; 23: 407-413.
108. Gamez G, Hammerschmidt S. Combat pneumococcal infections: adhesins as candidates for protein-based vaccine development. Curr Drug Targets 2012; 13: 323-337.
109. Talbot HK, Rock MT, Johnson C, et al. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 2010; 5: e14442.
110. Atsmon J, Kate-Ilovitz E, Shaikevich D, et al. Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine. J Clin Immunol 2012; 32: 595-603.